Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

What Kind of Vents Are Best as a Floor Register MINNESOTA, MN, UNITED STATES, March 28, 2026 /EINPresswire.com/ -- ...

Northwestern Medicine investigators have uncovered a missing link behind the harmful effects of autoantibodies linked to ...

PPST Solution’s expanded portfolio includes EA Elektro-Automatik for high-power DC power test solutions, an ideal ...

GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMDCTx001 is an investigational ...

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory ...

Researchers will join a new NIH-supported network working to develop novel approach methodologies that complement or replace ...

Kia's Product Planning chief gave us a surprisingly direct answer about whether the 2027 Telluride will replace or complement ...

Israel reportedly deploys Iron Beam laser defence system to intercept Hezbollah rockets amid regional escalation. Here’s how ...

Did Israel use its Iron Beam laser defence system to intercept Hezbollah rockets? Here’s what is confirmed, what remains ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...